The pro-survival proteins of the BCL-2 family regulate the survival of all cells, and genetic deletion models for these proteins have revealed which specific BCL-2 family member(s) is/are critical for the survival of particular cell types. A1 is a pro-survival BCL-2-like protein that is expressed predominantly in haematopoietic cells, and here we describe the characterisation of a novel mouse strain that lacks all three functional isoforms of A1 (A1-a, A1-b and A1-d). Surprisingly, complete loss of A1 caused only minor defects, with significant, although relatively small, decreases in γδTCR T cells, antigen-experienced conventional as well as regulatory CD4 T cells and conventional dendritic cells (cDCs). When examining these cell types in tissue culture, only cDC survival was significantly impaired by the loss of A1. Therefore, A1 appears to be a surprisingly redundant pro-survival protein in the haematopoietic system and other tissues, suggesting that its targeting in cancer may be readily tolerated. Cell Death and Differentiation (2017) 24, 534-545; doi:10.1038/cdd.2016.156; published online 13 Janaury 2017
The pro-survival proteins of the BCL-2 family prevent apoptosis 1 and studies using gene-targeted mice have revealed which cell types rely on which pro-survival protein for their survival. For example, Bcl-2 −/− mice exhibit thymic and splenic atrophy, a loss of fur pigment and die~30 days post birth from polycystic kidney disease, attributable to excess lymphocyte, melanocyte and renal epithelial cell apoptosis, respectively. [2] [3] [4] Bcl-X −/− mice die before E14.5 of embryonic development because of aberrant death of erythroid and neuronal cells. 5 The generation of chimaeric or tissue-specific Bcl-X −/− revealed a critical role for BCL-XL in the survival of developing lymphocytes 5 and platelets. 6, 7 Mcl-1 −/− embryos die before implantation (E3.5), 8 but conditional Mcl-1 deletion models have demonstrated an essential role for MCL-1 in the survival of haematopoietic stem cells, lymphocytes, neurons and cardiomyocytes. [9] [10] [11] [12] [13] [14] [15] Bcl-W −/− mice have impaired spermatogenesis. 16, 17 A1 remains the only pro-survival BCL-2 family member for which a knockout mouse strain has not been developed. A1 was first discovered as a GM-CSF-inducible gene with significant sequence similarity to BCL-2 and MCL-1, 18 and its human homologue BFL-1 was later identified in fetal liver. 19 Overexpression of A1 protected an IL-3-dependent cell line from growth factor deprivation-induced apoptosis, thus demonstrating its pro-survival function. 20 In mice, A1 expression is restricted to the haematopoietic compartment. 18 Human BFL-1 expression is more widespread, but also predominantly haematopoietic. 21 A1 can be upregulated by NF-κB signalling, and it has been proposed that A1/BFL-1 is important for the survival of several activated immune cell subsets through stimulation of antigen or cytokine receptors. [22] [23] [24] [25] Studies of A1 in mice are complicated by the presence of multiple isoforms that are the result of gene duplication events. Three isoforms (A1-a, A1-b and A1-d) are functional, whereas the fourth, A1-c, is a pseudogene because of a frameshift mutation that results in an early stop codon.
26 A1-a, -b and -d are nearly identical at both the DNA and protein levels, but their expression patterns vary between cell types and particular functions for each isoform are yet to be delineated. 27 Mice lacking the A1-a isoform have been generated, but showed only minor defects in neutrophils and mast cells, 28, 29 suggesting functional redundancy between the different isoforms. Other in vivo studies of A1 involved knockdown of all functional isoforms using transgenic expression of an shRNA. [30] [31] [32] [33] A1 knockdown caused a reduction in B cells, mast cells and dendritic cells, but knockdown in these models was usually incomplete and hence not equivalent to a knockout.
Herein we describe the characterisation of a novel mouse strain lacking all A1 proteins, with a focus on the immune cell subsets that have previously been proposed to rely on A1 for their survival. Our results demonstrate that complete loss of A1 has only a minor impact, with only conventional dendritic cells (cDCs) being substantially affected. These findings have important implications for the regulation of haematopoietic cell survival, and also inform on toxicities that may be expected from therapeutic targeting of A1.
Results
Generation of A1-deficient mice. The A1 −/− mouse strain was generated by sequential deletion of each A1 isoform (A1-a, A1-b and A1-d) in embryonic stem (ES) cells. The separate targeting constructs each contained a different antibiotic resistance cassette for positive selection, flanked by flippase recombination target sites ( Figure 1a and Supplementary Figure S1a) . The loci were targeted in the order of A1-a (Bcl2a1a), A1-d (Bcl2a1d) and then A1-b (Bcl2a1b). This third targeting introduced a loxP-flanked allele of Bcl2a1b to allow for its conditional deletion. Antibiotic resistance markers were removed by flippase-mediated recombination to yield the conditional A1 knockout allele (A1 fl ) that lacks Bcl2a1a and Bcl2a1d but has Bcl2a1b flanked by loxP sites. Two independent ES cell clones were used to generate the A1-deficient mice. A1 fl/+ mice were crossed with CMV-Cre T/+ mice, in which the CRE recombinase is expressed ubiquitously and constitutively. This produced the final knockout allele (A1 − ). Intercrossing of A1 +/ − mice generated the complete knockout mice (A1
−/−
).
Figure 1 For caption see page 536
Deletion of all A1 isoforms was confirmed by PCR using primers for each individual locus ( Figure 1a , Supplementary Figure S1c and Supplementary Table S2) . A1 −/− mice were born at the expected Mendelian frequency (Supplementary  Table S1 ) and proved fertile. They appeared outwardly normal up to 12 months of age and are currently being monitored further.
Western blotting was performed on activated B and T lymphocytes, stimulated with anti-IgM fragments or antibodies against CD3 and CD28, respectively, from wild-type and A1 −/− spleen using an A1-specific monoclonal antibody that recognises all three functional isoforms. 34 In wild-type cells, A1 was markedly upregulated by 4 h of stimulation, whereas no protein was detected in A1-deficient cells. This analysis showed no detectable compensatory upregulation of the other pro-survival BCL-2 family proteins, BCL-2, BCL-XL and MCL-1, in A1-deficient cells (Figure 1b) . We further quantitated the other pro-survival proteins by intracellular FACS staining of stimulated lymphocytes ( Figure 1c and Supplementary Figure S1d) . The ratios of the mean fluorescence intensities (MFIs) for the A1 −/− to wild-type cells centred around 1 (Figure 1c ), demonstrating that there was no appreciable up-or downregulation of any of these BCL-2 family proteins in the A1-deficient cells. The strong upregulation of BCL-XL in response to B cell receptor (BCR) or T cell receptor (TCR) stimulation verified that the cells had been successfully activated (Supplementary Figure S1e) . Together, these results demonstrate that our newly engineered A1 −/− mice lack all A1 protein forms and they also show that A1 is not essential for embryonic development.
A1-deficient mice have no defects in the B lymphocyte lineage. A1 has been postulated to be involved in B cell maturation based on the observation that pre-B cells lacking the kinase PDK1 undergo excess apoptosis that is correlated with the loss of A1 mRNA. Retroviral expression of A1 protected these knockout cells from apoptosis. 35 We determined the percentages and total numbers of pro/pre-, immature, transitional and mature B cell subsets in the bone marrow of A1 −/− mice by flow cytometry, but found no significant differences compared with wild-type mice (Figure 2a and Supplementary Figure S2a) .
In the A1 shRNA knockdown mice, there was a small reduction in follicular B cells in the spleen. 30 Subsequent studies using a conditional knockdown mouse model similarly showed that loss of A1 caused a reduction in the follicular B cell subset. 32 However, we found that the follicular as well as marginal zone B cell subsets in the spleen were comparable between the wild-type and A1 −/− mice ( Figure 2b and Supplementary Figure S2b ). There was a trend towards a reduction in B1a cells in the lymph nodes of the A1 knockout mice (Supplementary Figure S2b) Figure S2c) .
A1 was proposed to play a role in the survival of activated B cells. 36, 37 Accordingly, in the A1 shRNA knockdown mice, purified T2 and follicular B cells underwent increased BCR activation-induced apoptosis in culture. 30 We found that BCRstimulated B cell blasts from wild-type and A1 −/− mice underwent similar activation-induced apoptosis in vitro (Figure 2c ). Collectively, these findings demonstrate that complete loss of A1 does not cause marked defects in the B lymphoid lineage, at least within the conditions examined.
A1-deficient mice have a reduction in γδTCR T cells and memory CD4
+ T cells but otherwise have a normal T cell compartment. A1 expression is markedly upregulated in immature T cells during the process of pre-TCR selection, 38, 39 suggesting that A1 may promote cell survival during this critical developmental stage. Accordingly, the A1 knockdown mouse model had an increase in DN2 and DN3 thymocytes and a corresponding reduction in the DN4 and DP populations. 30 Flow cytometric analysis revealed that T cell development proceeded normally in A1 −/− mice, with no reductions seen in the DN1-4 progenitors, immature DP thymocytes or mature CD4 + or CD8 + populations compared with wild-type controls (Figure 3a and Supplementary Figure S3a) . Moreover, when A1 −/− thymocytes were treated in culture with apoptosis-inducing agents (etoposide, PMA, dexamethasone, ionomycin or the BCL-2/BCL-XL/BCL-W inhibiting BH3 mimetic ABT-737), they died at a rate comparable to wild-type thymocytes (Figure 3b and Supplementary Figure S3b) .
TCR stimulation was shown to cause an increase in A1 protein in mature T cells, 40, 41 suggesting that A1 may play a critical role in activated T cell survival. Our flow cytometric analysis revealed a small but significant decrease in the unconventional TCRγδ T cell population, but no differences were seen in the conventional TCRαβ T cells, including both Figure 1 Generation and validation of A1-deficient mice. (a) Schematic representation of the murine A1 gene locus and the three targeting constructs for A1-a (Bcl2a1a), A1-d (Bcl2a1d) and A1-b (Bcl2a1b). F5, FRT and F3 sites were targets for Flpe-mediated recombination to remove the antibiotic resistance cassettes, once all three targeting constructs had been inserted. Bcl2a1a and Bcl2a1d are constitutively deleted after Flpe recombination, and Bcl2a1b is flanked by loxP sites. Intercrossing mice carrying the conditional knockout allele with the CMV-Cre transgenic mouse enabled CRE-mediated recombination to remove Bcl2a1b for the constitutive knockout. The lox5171 and attB or attP sites were used for diagnostic in vitro deletion tests through the multiple rounds of gene targeting. Numbers and dotted lines indicate sites for PCR primers, described in Supplementary Table S2 Figure S4c) . Interestingly, the central memory-and effector memory-like T reg populations in the spleen were also reduced in the A1-deficient mice ( Figure 4c ). Therefore, the reduction of the CD44 + memory phenotype populations appears to be specific to CD4 + T cells. To study the role of A1 in the activated T cells, CD4 + cells were isolated from A1 −/− and wild-type mice and subjected to stimulation with CD3 antibodies alone or in combination with CD28 antibodies or IL-2. Perhaps surprisingly, there was no discernable difference in proliferation, rate of cell division or survival between T cells from A1 −/− and wild-type mice ( Figure 4d and Supplementary Figure S4d) .
Thus, the only T cell populations that are slightly affected by the loss of A1 are the TCRγδ T cells, the physiological impact of which has not been explored, and T reg cells as well as conventional CD4 + T cells with a CD44 + memory phenotype.
Loss of A1 decreases the numbers of cDCs and impairs their survival in vitro, but has no impact on other innate immune cell types. Neutrophils from mice lacking the A1-a isoform exhibited abnormally increased apoptosis in culture. 28 Similarly, A1 shRNA knockdown mice had a reduction in granulocytes. 30 A combined dependency on both A1 and MCL-1 was recently revealed in neutrophils, but in particular A1 expression was dramatically increased upon stimulation with either LPS or GM-CSF. 42 We therefore examined the impact of complete A1 loss on granulocyte numbers in vivo and on their survival in culture. At steady −/− mice by culturing bone marrow cells in the presence of stem cell factor (SCF) and IL-3. After 3 weeks of culture, mast cell survival was assessed after cytokine withdrawal with or without FcεR crosslinking with IgE. Data are representative of three independent mast cell lines derived from individual mice per genotype, with treatments measured in triplicate state in the bone marrow and spleen, there were no differences in either the total numbers or proportions of neutrophils or macrophages (Figure 5a and Supplementary Figure S5a) . Moreover, the numbers of other granulocytic cell types (e.g., eosinophils, monocytes) were all normal in the blood of A1-deficient mice (Supplementary Figure S5b) . To examine neutrophil apoptosis in culture, neutrophils were FACS-sorted from A1 −/− and wild-type mice and then stimulated with GM-CSF or kept in simple medium. Regardless of the treatment applied, there was no significant difference in the survival between wild-type and A1-deficient granulocytes (Figure 5b ).
Mast cells are another myeloid cell type that were found to be affected by both A1-a deletion and shRNA-mediated knockdown of A1 in mice. 29, 31 Therefore, we investigated mast cell numbers in the peritoneal cavity. Again, there were no differences in the numbers of mast cells between the A1-deficient and wild-type mice (Figure 5c ). Mast cells were grown in vitro by culturing bone marrow progenitors in the presence of stem cell factor (SCF) and IL-3. The A1 Figure S5c) . Survival assays were performed with these differentiated mast cells after cytokine withdrawal or concomitant stimulation with FcεR crosslinking (Figure 5d ), the calcium ionophore ionomycin, LPS or IL-33 (Supplementary Figure S5d) . No difference in survival was observed between A1-deficient and wild-type mast cells under any of these conditions. High A1 protein expression levels were recently noted in cDCs. 33 Furthermore, studies using the shRNA knockdown of A1 in mice revealed a marked reduction in cDCs and a compensatory increase in the proportions of plasmacytoid DCs (pDCs). We have been able to recapitulate these results in the A1 −/− mice, in which we also observed a small but significant decrease in both the CD11b + and CD8 + cDC populations in the spleen (Figure 6a ). There was also a trend towards a reduction in the migratory DC subsets in the lymph nodes, though this was not statistically significant (Supplementary Figure S6) . A role for A1 in the survival of cDCs was substantiated by in vitro cell survival assays. Loss of A1 significantly reduced the numbers of live CD11b + as well as CD8 + cDCs after 24 h in culture compared with their wild-type counterparts. When calculated as the percentage of cells recovered compared with the initial input, there was an approximately threefold decrease in the survival of A1 −/− cDCs ( Figure 6b) .
Collectively, these results reveal that A1 has an indispensable role in the survival of cDCs, but either plays no role or has a role overlapping with that of other pro-survival BCL-2 family members in other myeloid cell populations.
Discussion
The BCL-2 family member A1 has been significantly more challenging to study than its pro-survival relatives, BCL-2, BCL-XL, BCL-W and MCL-1. This is because of the quadruplication of the A1 gene in mice that makes generating a complete knockout mouse only possible by multiple sequential rounds of gene targeting. This was achieved, and here we describe the characterisation of mice that are completely deficient for all A1 proteins.
The lack of an overt phenotype was somewhat unexpected given the previous reports of prominent A1 expression in B and T lymphocytes, neutrophils, mast cells and dendritic cells. When examining the steady-state haematopoietic cell subset composition of the A1 −/− mice by flow cytometry, we observed relatively small, although significant, decreases in the numbers of TCRγδ T cells, T reg cells, CD4 + memory T cells and cDCs. For the cDCs, we also found a clear dependence on A1 for survival in culture. This suggests that A1 may be an important factor for cDC survival under conditions of stress. However, this remains to be demonstrated in vivo.
It was surprising to see no differences in ex vivo cell survival assays for the other leukocyte subsets, given that A1 is upregulated in response to several stimuli that we had tested in these assays. The reduction in antigen-experienced CD4 + memory T cells in the spleen appeared to be in accordance with the A1 upregulation that occurs upon TCR stimulation. However, in vitro assays using mitogenic antibodies against CD3 and CD28 or IL-2 did not reveal any survival defects. Given that this was an in vitro test, it is possible that these signals are stronger than would be physiologically relevant, and may overwhelm the normal processes that control cell survival. This nonphysiological response may induce survival programmes that are not reliant on A1. Alternatively, the prosurvival activity of BCL-XL, which is also substantially upregulated upon TCR stimulation, 43 may fulfil the survival needs of the activated T cells. The in vivo T cell stimulation has been examined using models of influenza and chronic LCMV infection, but no abnormalities were seen in A1 −/− mice. 44 Furthermore, upon immunisation with NP-KLH, A1 −/− mice failed to reveal any B cell activation defects in vivo. 44 It has been reported that in mice lacking the A1-a isoform, the inflammatory response to infection with Toxoplasma gondii was less severe compared with wild-type controls in terms of overall peritoneal leukocyte cellularity, but the proportions of granulocytes recruited to the peritoneal cavity were comparable. 45 This suggests that loss of A1 may impair the survival of certain cell types of the immune system to a minor extent, but not enough to preclude A1-deficient mice to respond adequately to infectious challenges. It remains, however, possible that the type of immune challenge that relies heavily on A1 has not yet been experimentally tested. Thus, there is room for exploration of a host of parasitic and bacterial infection models. In fact, A1 was recently implicated in Mycobacterium tuberculosis infection, as A1 mRNA was found to be substantially upregulated in infected macrophages, suggesting that A1 may promote the survival of such infected cells. 46 Interestingly, a recent study showed that BCL-XL-specific BH3 mimetics potently kill Legionella-infected macrophages and thereby protect mice from pathology induced by these bacteria. 47 Should loss of A1 kill Mycobacterium tuberculosis macrophages, it would be of interest to generate A1-specific BH3 mimetics to test for treatment of tuberculosis.
Many of the results from our studies of the A1 −/− mice are in discordance with previous investigations of the in vivo function of A1 using A1-a-deficient mice or A1 shRNA knockdown mice. For example, the A1-a knockout mice exhibited defects in neutrophil and mast cell survival in culture. 28, 29 We found no abnormal reduction of either of these myeloid cell populations in our A1 −/− mice, and did not observe any significant defect in their survival in culture, both with and without stimulation. Although we have not performed in vivo assays in which neutrophils or mast cells are challenged, for example by microbes or allergens, our data do not suggest any impairment in this regard. Differences in genetic background between the A1-a-deficient and our A1 −/− mice may explain the disparities, as previous reports have described an impact of genetic background on cell death assays. 48 Our analyses of mice lacking all functional A1 isoforms reveal that there is functional redundancy with the other prosurvival members of the BCL-2 family. We found no evidence for dramatic compensatory effects such as upregulation of MCL-1, BCL-XL or BCL-2 or downregulation of BIM in the cells of A1
−/− mice that we have examined. However, one could argue that the germline deletion of all A1 isoforms removes any pressure for upregulation of the other pro-survival proteins to perform A1 function, because A1 was never present. Our model is limited in that it is not possible to conditionally delete all A1 isoforms, as the conditional knockout allele lacks Bcl2a1a and Bcl2a1d, with only Bcl2a1b flanked by loxP sites.
Analyses have been performed of acute deletion of A1-b, through the use of a RosaCreERT2; A1 fl/fl tamoxifen-inducible Cre model, but these tests similarly did not show any differences in cell survival compared with control animals (data not shown).
Arguably, the doxycycline-inducible A1 shRNA transgenic knockdown model could address this question of the relative impact of germline versus acute A1 gene deletion. However, there were many discrepancies between the shRNA-mediated knockdown of A1 and our constitutive A1 knockout mice that make it difficult to compare the two models. In the constitutive knockdown mice, 30 ,31 significant differences were observed in double-negative thymocytes, mature B cells and granulocytes, none of which could be recapitulated in the A1-deficient mice. These inconsistencies are likely to have arisen from the fact that there is much less control of decreasing A1 expression when using transgenic expression of the A1 shRNA compared with a complete A1 knockout. Furthermore, off-target effects, such as undue stress to cells because of expression of the A1 shRNA transgene, may occur. These limitations are evident when comparing the original A1 shRNA knockdown mice 30 with the inducible A1 shRNA model, 32 as the aforementioned defects in the former were not reflected in the latter. On balance, given the genetic complications from having four copies of the A1 gene in mice, we believe that our current mouse model is the best to study A1 function in vivo.
The finding that complete loss of A1 has only minor impact on the whole animal may have interesting implications for the development of drugs that inhibit this pro-survival protein, as they would be predicted to have only minor toxicity. BH3 mimetic compounds, akin to the recently FDA approved BCL-2-specific inhibitor Venetoclax (ABT-199), 49 or the newly described MCL-1 inhibitor S63845 soon entering first clinical trials, 50 but inhibiting specifically A1, may be useful for the treatment of certain types of lymphoma, melanoma and stomach cancer, as these cancers were found to express abnormally high levels of A1. 21 In conclusion, our studies reveal that A1 is not a vital prosurvival protein in normal physiology. Our gene-targeted mice will be useful (and will be made freely available) to examine the role of A1 in cancer development, infectious diseases and other conditions of stress.
Materials and Methods Generation of A1
−/− mice. The A1 fl/+ mice were generated by Taconic Biosciences GmbH (Cologne, Germany). The targeting constructs ( Figure 1a) were transfected into the Taconic Biosciences C57BL/6NTac ES cell line, sequentially in the order of A1-a (Bcl2a1a), A1-d (Bcl2a1d) and A1-b (Bcl2a1b). Each targeting construct contained a unique antibiotic resistance cassette for positive selection, and thymidine kinase cassette for negative selection. For Bcl2a1a, both exons as well as a~1.5 kb region upstream (promoter region) were targeted (~7 kb region in total). For both Bcl2a1d and Bcl2a1b, only their exons 1 and the promoter regions (1.5 kb upstream) were targeted (~2.5 kb regions). Bcl2a1a and Bcl2a1d were targeted for deletion, whereas the Bcl2a1b targeting construct replaced the wild-type allele with the promoter and exon 1 of Bcl2a1b flanked by loxP sites (Supplementary Figure S1a) . For diagnostic in vitro deletion tests, that is, to verify that targeting of A1 isoforms had occurred on the same chromosome, lox5171 and attB/P sites were also inserted and confirmed by Southern blotting (Supplementary Figure S1b) .
Successfully targeted ES cell clones were selected and microinjected into BALB/c blastocysts isolated at dpc 3.5. Recovered blastocysts were transferred into pseudopregnant mice and resultant chimaerism of offspring was determined by coat colour contribution of ES cell-derived cells. Highly chimaeric mice were bred to the C57BL/6 strain, with mating partners from the C57BL/6-Tg(CAG-Flpe)2 Arte transgenic mice carrying the FLP recombinase (FLPe). The action of the FLP recombinase removed the antibiotic resistance cassettes, giving the Bcl2a1d and Bcl2a1a constitutive KO/Bcl2a1b conditional KO allele. Presence of the FLPe transgene and loss of antibiotic resistance cassettes were confirmed by PCR (see supplementary Table S2 for details of PCR primers).
Mice bearing this allele were transferred to the Walter and Eliza Hall Institute (WEHI) animal facility, where they were crossed with C57BL/6 deleter CMV-Cre mice 51 to breed out the FLPe transgene and to cause recombination at the loxP sites flanking A1-b to produce the constitutive knockout allele (A1 +/ − mice). A1 +/ − ; Cre T/+ mice were crossed with A1 +/ − mice in order to generate A1 −/− mice. Two independent colonies of A1 −/− were generated from two independent A1 genetargeted ES cells. All animal experiments were performed in accordance with ethics criteria as set out by the WEHI Animal Ethics Committee.
Genotyping was performed by PCR to confirm loss of the FLPe transgene, presence or absence of the CMV-Cre transgene, deletion of Bcl2a1a/Bcl2a1d, the floxed Bcl2a1b allele and, later, the loss of the Bcl2a1b allele (Supplementary Figure S1c and Supplementary Table S2 ).
Haematopoietic analysis. The haematopoietic organs -thymus, spleen, bone marrow (both tibias and femurs) and lymph nodes (axial, inguinal, brachial and one mesenteric) -were harvested from 6-12-week-old mice and then used for FACS analysis, western blotting or in vitro experiments. Peripheral blood was collected by eye bleed, and analysed using the ADVIA automated haematology system (Bayer, Tarrytown, NY, USA). ), and BIM (3C5, WEHI). Stained cells were analysed with LSRII, Fortessa1 or Fortessa X20 analysers, and cell sorting was performed using the Aria high-speed cell sorter (Becton Dickson, Franklin Lakes, NJ, USA). FACS data were analysed with FlowJo software (Treestar, Ashland, OR). Cell numbers of populations were determined using whole organ cell counts that were determined on the CASY counter (Schärfe System GmbH, Reutlingen, Germany).
Western blotting. Cell lysates were prepared from single-cell suspensions of FACS-sorted spleen and thymus. Lysates were prepared in Onyx buffer (20 mM Tris-HCl pH 7.4, 135 mM NaCl, 1.5 mM MgCl 2, 1 mM EGTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol) with added protease inhibitor cocktail (Roche, Basel, Switzerland). Protein concentration was determined by Bradford assay using the Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA, USA). Proteins were size fractionated by gel electrophoresis on NuPAGE 10% Bis-Tris 1.5 mm gels (Life Technologies) in MES buffer and then transferred onto nitrocellulose membranes (Life Technologies) using the iBlot membrane transfer system. The following primary antibodies were diluted in 5% skim milk in PBS-T buffer to probe for the pro-survival BCL-2 family proteins: monoclonal rat anti-mouse A1 (clone 6D6, WEHI antibody facility), 34 monoclonal rat anti-mouse MCL-1 (clone 19C4-15, WEHI antibody facility), 52 polyclonal rabbit anti-mouse BCL-XL (BD Biosciences 610212) and monoclonal mouse anti-BCL-2 (clone 7, BD Biosciences). Probing for HSP70 (antibody clone N6, gift from Dr. R Andersson, Peter MacCallum Cancer Research Centre, Melbourne, VIC, Australia) was used as a protein loading control. Secondary anti-rat/mouse/rabbit IgG antibodies conjugated to HRP (Southern BioTech, Birmingham, AL, USA) were applied, followed by Luminata Forte Western HRP substrate (Millipore, Billerica, MA, USA) for band visualisation. Membranes were imaged using the ChemiDoc XRS+ machine with ImageLab software (Bio-Rad).
B cell stimulation. B cell blasts were generated by stimulation of splenocytes cultured in DME medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% (v/v) FCS (Sigma-Aldrich, St Louis, MO, USA), 40 mM sodium bicarbonate, 1 mM HEPES, 100 U/ml penicillin/streptomycin, 0.0135 mM folic acid, 0.24 mM L-asparagine monohydrate, 0.55 mM L-arginine monohydrochloride, 50 μM β-mercaptoethanol, and 100 μM asparagine (hereafter called FMA medium) with 2 μg/ml anti-IgM F(ab')2 fragments (Jackson ImmunoResearch, West Grove, PA, USA) in the presence of IL-4 and IL-5 or with cytokines alone as a control. Cells were seeded at 1 × 10 5 cells/well and cultured in 96-well plates, or 3 × 10 6 cells/well in 6-well plates for intracellular FACS staining. Cell survival was analysed by staining with Annexin-V conjugated to FITC or Alexafluor-647 and PI (5 μg/ml) followed by flow cytometric analysis.
Thymocyte death assays. Unsorted thymocytes were placed in culture in FMA medium alone or with addition of ABT-737 (inhibitor of BCL-2, BCL-XL and BCL-W; 0.5 μM), dexamethasone (0.5 ng/ml), etoposide (0.5 μg/ml), ionomycin (0.1 μg/ml) or PMA 0.5 ng/ml). Cells were seeded at 1 × 10 5 cells/well and cultured in 96-well plates. Cell survival was analysed using flow cytometry after staining with Annexin-V conjugated to FITC or Alexafluor-A647 and PI (5 μg/ml).
T cell stimulation. T cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FCS, 10 mM Hepes, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM GlutaMAX, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate (all from Invitrogen, Carlsbad, CA, USA) and 50 μM β-mercaptoethanol (Sigma). CD4 + T cells were isolated from mouse lymph nodes (inguinal, axillary, brachial and superficial cervical) by negative selection using the EasySep Mouse CD4 + T cell Isolation kit (StemCell Technologies, Vancouver, BC, Canada). Purity was typically 495%. CD4 + T cells were stimulated with plate-bound anti-CD3 antibody (10 μg/ml, clone 145-2C11, WEHI monoclonal antibody facility), with 2 μg/ml anti-CD28 antibody (clone 37.51, WEHI monoclonal antibody facility) or 10 U/ml human IL-2 (h-IL-2) (Peprotech, Rocky Hill, NJ, USA) added to the cultures as indicated. All T cell cultures contained 25 μg/ml anti-mouse IL-2 antibody (clone S4B6, WEHI monoclonal antibody facility) that blocks the activity of mouse IL-2 in vitro but does not block human IL-2. 53 To track cell division, cells were labelled with 5 μM CellTrace Violet (CTV) (Invitrogen) according to the manufacturer's instructions. Cells were seeded at 1 × 10 4 cells/well and cultured in 96-well plates. A known number of beads (Rainbow calibration particles BD Biosciences) were added to samples immediately before analysis and the ratio of beads to live cells was used to calculate the absolute cell number in each sample. PI was used for dead cell exclusion at 0.2 μM. The mean division number (MDN) is calculated using the precursor cohort method as described previously. 54 For intracellular FACS staining, 3 × 10 6 cells/well were seeded in 6-well plates coated with anti-CD3 antibody as above.
Neutrophil survival assays in culture. Bone marrow was collected from the tibias and femurs of mice, and then FACS-sorted for Gr1 hi cells. Cells were plated at 3 × 10 4 cells/well in 96-well plates in either medium alone (RPMI-1640, 10% (v/v) FCS) or medium containing 10 ng/ml murine recombinant GM-CSF (kindly provided by Dr. Jian-Guo Zhang of WEHI). Cell survival was determined by flow cytometry after staining with Annexin-V-FITC and PI.
Generation of bone marrow-derived mast cells and stimulation in vitro. Bone marrow was collected from the tibias and femurs of mice and placed in culture in mast cell medium (DMEM, 10% FCS, 2 mM glutamine, 0.1 mM non-essential amino acids, 1 mM pyruvate and 50 μM β-mercaptoethanol) supplemented with fresh mouse SCF (12.5 ng/ml, recombinant protein produced in-house and kindly provided by Dr. Jian-Guo Zhang of WEHI) and IL-3 (supernatant from X63/0-IL-3 cells 55 ) weekly. After 3 weeks of culture, cells were assessed by flow cytometry for mast cell differentiation by staining for FcεR and c-KIT. Subsequent experiments using these mast cells were all performed within 6 weeks. For FcεR crosslinking survival assays, mast cells were incubated overnight with IgE specific for TNP (supernatant from TiB142 cells kindly provided by Dr. Graham Mackay, University of Melbourne, Parkville, Australia) before washing with PBS to remove cytokines and stimulated with TNP-BSA (100 ng/ml; Biosearch Technologies, Novato, CA, USA). As a control, cells were not incubated with IgE, but subjected to the same incubation times and wash steps. For ionomycin, LPS and IL-33 treatment survival assays, cells were washed to remove cytokines and then treated with 1 μg/ml ionomycin, 5 μg/ml ultrapure LPS (E. coli 0111:B4 strain-TLR4 ligand, InvivoGen, San Diego, CA, USA), 10 ng/ml IL-33 (produced in-house and kindly provided by Dr. Ajithkumar Vasanthakumar of WEHI) or medium alone (no cytokines added). Cells were plated at 1-6 × 10 4 cells/well in 96-well plates. Cell survival was analysed by flow cytometry after staining with Annexin-V and PI.
Dendritic cell analysis. Spleen and pooled subcutaneous lymph node (axial, brachial, inguinal and cervical) suspensions were prepared by digestion in Collagenase/Dnase-1 as previously described. 56 Red blood cells in spleen were lysed in 0.156 M NH 4 Cl unless further enrichment was required. Anti-CD11c, CD11b, CD8, Siglec-H, CD326 and CD103 (BD Biosciences) were used to identify dendritic cell subsets by flow cytometry, with absolute cell numbers determined by the addition of fluorochrome-conjugated calibration beads (BD Biosciences) added directly to samples. Data were collected using a FACSverse (BD Biosciences) and analysed using FlowJo software (Treestar).
For cell culture assays, splenocytes were enriched for DCs using a Nycodenz density gradient as previously described (Vremec et al., 2000) . Enriched cells were seeded at 2 × 10 5 cells per well in 200 μl RPMI supplemented with 10% FCS in a flat bottom plate, with cells harvested immediately (uncultured) or after overnight culture in 10% CO 2 at 37°C. Upon harvesting, cells were stained for cell surface markers, and cell survival and live cell numbers were determined by flow cytometry after adding fluorochrome-conjugated calibration beads (BD Biosciences) and PI.
Statistical analyses. All statistical analyses were performed using Prism software (GraphPad, La Jolla, CA, USA), with the Mann-Whitney U-test used to determine statistical significance defined by a P-value of o0.05. Specifically, *Po0.05, **Po0.01 and ***Po0.001. All data are presented as mean ± S.E.M., unless otherwise indicated.
